

CURRICULUM VITAE

Personal:

Name: Michael R. Bishop, M.D., F.A.C.P

Home Address and Phone No.: -----(b)(6)-----
-----(b)(6)-----
-----(b)(6)-----
-----(b)(6)-----

Office Address and Phone No.: Division of Hematology and Oncology
Medical College of Wisconsin
Clinical Cancer Center – 4th Floor- Room C4194
9200 West Wisconsin Avenue
Milwaukee, WI 53226
Phone: (414) 805-4688
Phone: (414) 805-4600
FAX: (414) 805-4606
E-mail: mbishop@mcw.edu

Birth Date and Place: -----(b)(6)-----
-----(b)(6)-----

Education:

-(b)(6)- B.S. (Biology - Ecology, Ethology, and Evolution)
University of Illinois – Urbana-Champaign
Urbana-Champaign, Illinois

1985 M.D.
University of Illinois College of Medicine
Chicago, Illinois

Post-Degree Training:

1985 - 1986 Internship, Internal Medicine
Northwestern Memorial Hospital
Chicago, Illinois

1986 – 1988 Residency, Internal Medicine
Northwestern Memorial Hospital
Chicago, Illinois

1988 - 1991
Fellowship, Hematology/Oncology
Loyola University Medical Center
Maywood, Illinois

Academic Appointments:

4/2011 – present
Professor of Medicine
Head, Section of Adult Hematologic Malignancies
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI

6/2007 – 2/2011
Senior Investigator (Tenured)
National Cancer Institute
National Institutes of Health
Bethesda, MD

8/2005 – 4/2007
Deputy Branch Chief (acting)
- Director, Medical Oncology Fellowship Program
- Chief, Medical Oncology Clinical Services
- Head, Office of Protocol Administration
- Head, Office of Research Nursing
Medical Oncology Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

3/1999 – 5/2007
Investigator (Tenure Track)
National Cancer Institute
National Institutes of Health
Bethesda, MD

3/1999 – 2/2011
Clinical Head
Experimental Transplantation
And Immunology Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

7/1997 - 2/1999
Associate Professor of Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center
Omaha, Nebraska

- 7/1997 - 2/1999 Associate Professor of Pediatrics (Courtesy)
Section of Pediatric Hematology/Oncology
University of Nebraska Medical Center
Omaha, Nebraska

- 1997 - 2/1999 Program Member, Developmental Therapeutics
University of Nebraska Medical Center-Eppley Cancer
Center
Omaha, Nebraska

- 1992 - 7/1997 Assistant Professor of Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center
Omaha, Nebraska

- Assistant Professor of Pediatrics (Courtesy)
Section of Pediatric Hematology/Oncology
University of Nebraska Medical Center
Omaha, Nebraska

- Assistant Professor (Courtesy)
Eppley Institute for Research in Cancer and Allied
Diseases University of Nebraska Medical Center
Omaha, Nebraska

- 1995 – 2/1999 Graduate Faculty Member
University of Nebraska Medical Center
Omaha, Nebraska

- 1991 - 1992 Assistant Professor of Medicine
Section of Hematology/Oncology
University of Kentucky Medical Center
Lexington, Kentucky

Board Certification and Medical License:

Diplomate, American Board of Internal Medicine - Internal Medicine
 Diplomate, American Board of Internal Medicine – Medical Oncology
 Eligible, American Board of Internal Medicine - Hematology

- Illinois -----(b)(6)-----
- Kentucky -----(b)(6)-----
- Nebraska -----(b)(6)-----
- Wisconsin -----(b)(6)-----

Grants/Contracts:

7/1/98 - 6/30/99

“BCR/ABL Positivity of Early Stem Cells from CML Patients”
Funding source, Nebraska Dept. of Health and Human Services
Funding source, Nebraska Department of Health, LB506
Cost of entire project \$29,658
PI: Dr. John Jackson
Co-I: Dr. Bishop

1/28/98 - 7/31/98

“-----
------(b)(4)-----

-----”
Funding source, Intrabiotics
Cost of entire project \$--(b)(4)(b)(6)--
Co-PI’s: -----(b)(6)---- and Dr. Bishop
Co-I’s: -----(b)(6)-----

4/1/98 - 3/31/99

“A Comparison of G-CSF with the -----(b)(4)-----
-----for the Mobilization -----(b)(4)-----
-----in Normal Individuals”
Funding source, Immunex Corporation
Cost of entire project \$--(b)(4)(b)(6)----
PI: Dr. Bishop

11/97 - 7/98

“------(b)(4)-----
-----”
Funding source, U.S. Bioscience, Inc.
Cost of entire project \$--(b)(4)(b)(6)--
PI: Dr. Bishop

7/1/97-6/30/98

“New and Novel Approaches to Allo- and Xeno-tolerance”
Funding source, College of Medicine and University Hospital
Cost of entire project \$--(b)(4)(b)(6)--

PI: Dr. --(b)(6)--
Co-I: Dr. Bishop

6/1/97-5/31/98

"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled
Trial of Recombinant Human Granulocyte-Macrophage Colony-
Stimulating (rhu GM-CSF) -----(b)(4)-----
-----."
Funding source, Immunex
Costs of entire project \$--(b)(4)(b)(6)---
PI: Dr. Bishop

- 1/1/97-6/30/98 "A prospective multi-center observational study to evaluate the adverse events and clinical outcomes associated with the use of GM-CSF and G-CSF"
 Funding source, University Health Consortium
 Costs of entire project \$--(b)(4)(b)(6)---
 PI: Dr. Bishop
- 1/1/97-12/31/97 "Prospective evaluation of acute graft-versus-host disease in patients undergoing allogeneic blood stem cell transplantation."
 Funding source, UNMC Outcomes Research Grant
 Cost of entire project \$--(b)(4)(b)(6)---
 PI: Dr. Bishop
- 7/1/96-6/30/98 "Anti-tumor therapeutic potential of umbilical cord blood."
 Funding source, Elsa U. Pardee Foundation.
 Cost of entire project \$--(b)(4)(b)(6)---
 PI: Dr. --(b)(6)---
 Co-I: Dr. Bishop
- 01/01/96-12/31/98 "A comparison of granulocyte colony stimulating (G-CSF) versus placebo -----(b)(4)-----".

 Funding source, Amgen, Inc.
 Cost of entire project \$--(b)(4)(b)(6)--- (Investigator initiated)
 PI: Dr. Bishop
 Co-I: ---(b)(6)----
- 10/01/94-06/30/99 "Developmental therapeutics: Oligonucleotide therapy; peripheral stem cell transplantation".
 Funding source, LB595, \$--(b)(4)(b)(6)--total grant.
 Co-PIs: Drs. Bishop and ---(b)(6)---
 Co-Investigators: -----(b)(6)-----

- 11/01/93-04/30/2001 "Therapy groups to study T-cell depletion in unrelated donor marrow transplantation."
 Funding source, NIH, NHLB1 HV92-24.
 Cost of entire project, \$2,016,124.
 PI: Dr. John Wagner, Univ. of Minnesota
 Co-Investigators: Drs. Bishop, Warkentin, Gross

Editorial Boards/Journal Review:

Editorial Boards:

American Society of Clinical Oncology Compendium (2005 – 2007)
Cancer Trials – National Cancer Institute (2000 – 2002)
Current Stem Cell Research & Therapy (2005 – present)
Journal of Clinical Oncology
- Transplantation (2006 – 2009)
Experimental Biology and Medicine (2006 –2009)
Biology of Blood and Marrow Transplantation (2010 – present)

Ad-hoc Journal Reviews:

American Journal of Medicine
American Journal of Gastroenterology
American Journal of Hematology
American Journal of the Medical Sciences
Annals of Oncology
Biology of Blood and Marrow Transplantation
Blood
British Journal of Haematology
Bone Marrow Transplantation
Cancer
Cancer Control: Journal of the Moffitt Cancer Center
Cancer Research
Clinical Cancer Research
Cytotherapy
European Journal of Hematology
Experimental Hematology
Expert Review of Anticancer Therapy
Expert Opinion on Biologic Therapy
Haematologica
Journal of Clinical Oncology
Journal of Hematotherapy
Leukemia
Leukemia & Lymphoma
Leukemia Research
Oncology
The Oncologist
Supportive Oncology

Honors & Awards:

Veterans of Foreign Wars Academic Scholarship -----(b)(6)-----

James Scholar of University of Illinois (Urbana-Champaign), ---(b)(6)---
Dean's List - University of Illinois (Urbana-Champaign), ----(b)(6)-----
Illinois General Assembly Scholarship, --(b)(6)--- - 1985
Senior Class President, University of Illinois College of Medicine, 1984 - 1985
Outstanding Teaching Resident Award, 1988
- Department of Internal Medicine, Northwestern Medical School
UNMC Leadership Institute 1994
American Cancer Society Science Writers' Meeting, March 1994
Included in The Best Doctors in America:
Central Region 1996 – 1998
National 2001, 2002, 2003, 2007, 2008-2009, 2009-2010, 2011-2012
UNMC Top Teachers in the Department of Internal Medicine 1996, 1997, 1998
2003 National Institutes of Health Distinguished Clinical Teacher Award
Board Member (honorary), Cancer Research Assistance Fund, Tulsa, Oklahoma (non-profit
patient advocacy group promoting patient participation in cancer research)
NIH Senior Leadership Program (Fall 2007)

Memberships in Professional Societies:

Member, American Society of Clinical Oncology
Member, ASCO OnLine Committee (1996-2000)
Member, ASCO Intellectual Properties Task Force (1999-2001)
Member, ASCO Sponsorship Committee (2000-2002)
Member, ASCO Scientific Program Committee – Leukemia, Lymphoma &
Transplantation (2003-2005)
Session Moderator – Multiple Myeloma, 2004 Annual Meeting
Member, Cancer Education Committee – Compendium Editorial Board Subcommittee
(2005-2008)
Reviewer, Annual Meeting Education Book, (2009, 2010)
Member, Cancer Research Committee (2009-present)
Member, American Society of Hematology
Session moderator - Myeloproliferative Disorders, 2007 Annual Meeting
Liaison, Governmental Affairs Committee (NCI Director Appointment; 2007-2011)
Member, 2011 ASH Daily News Editorial Board
Member, Committee on Communications (2012-2016)
Member, Leukemia Society of America (1996-1999)
Member, American Society for Blood and Marrow Transplantation (ABMTR)
Member, Leukemia Working Committee of the ABMTR
Chairman, Nominations Committee (2000 – 2003)
Fellow, American College of Physicians
Member, European Society for Cancer Immunology and Immunotherapy

Committee Assignments/Invited Participation in National/International Meetings:

Member, International Bone Marrow Transplant Registry (IBMTR)
Secretary-Treasurer, Executive Committee (2004-2006)
Center for International Blood and Marrow Transplant Research (CIBMTR)
Acute Leukemia Committee (committee member)
Chronic Leukemia Committee (committee member)
Lymphoma Working Committee (committee member)
Co-Chair (2010-2015), Solid Tumor Working Committee
Session Moderator – GVL/GVHD and Cell Processing, 2007 Tandem Transplant Meeting
Member, Cancer and Leukemia Group B (CALGB)
Member, Core member - Bone Marrow Transplant Committee (1997-1999; 2002-2004)
Member, Core member - Leukemia committee (1997-1999)
Board Member, Nebraska Chapter of Leukemia Society of America (1995-1999)
Education Board Member, Wisconsin Chapter of Leukemia Lymphoma Society (2011 – present)
NCCN - Practice Guidelines and Outcomes Data in Oncology Committee (1998-1999)
Organizing Committee and Session Moderator, First International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma, April 10-12, 2003, New York, New York
Invited participant, NIH Workshop on Allogeneic Hematopoietic Stem Cell Transplantation for Auto-immune Diseases, March 12-13, 2005, Bethesda, MD
Invited participant, Second Allogeneic Transplantation in Solid Tumors, October 7-8, 2005, Stresa, Italy
Member, Data and Safety and Monitoring Board, Blood and Marrow Transplant Clinical Trials Network (2006 - present)
Vice-chair (2007- present)
Organizing Committee and Session Moderator, Second International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma, May 18-20, 2006, New York, New York
Co-chair, NCI-sponsored International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation, November 2-3, 2009, Bethesda, Maryland
Co-chair, Organizing Committee
Co-chair, Planning Committee
Scientific Program Organizing Committee, 2010 Blood and Marrow Transplant Tandem Meetings, February 24-28, 2010, Orlando, Florida, USA
Chair, Abstract Review Committee
Faculty member, 2011 ASCO/AACR Methods in Clinical Cancer Research Workshop, July 30 - August 5, 2011, Vail, Colorado
Consultant, FDA Cellular, Tissue and Gene Therapies Advisory Committee, September 22-23, 2011
Member, FDA Cellular, Tissue and Gene Therapies Advisory Committee (2012 – present)

NCI/NIH/HHS Assignments:

Member, NIH Clinical Center Chemotherapy Errors Prevention Task Force (2000-2001)

Member, NIH Operational Review of the Clinical Center Nutrition Department (2002)
Member, NCI Intramural Advisory Board (2000 – 2002)
Member, NIH Clinical Center Cost-Management Task Force #1 (2001-present)
Clinical Investigators Committee, MOCRU, National Cancer Institute (1999- present)
Review of Transplantation indications for the Federal Employees Health Benefits Program, Office of Insurance Programs (2000, 2001, 2002, 2004, and 2006)
Intramural Advisory Board, National Cancer Institute (2000 – 2002)
NIH Clinical Center Chemotherapy-Related Error Prevention Task Force (2000)
Chairman, Medical Oncology Clinical Research Unit Chief Search Committee (2001)
Chairman, NCI Patient Outreach and Accrual Committee (2002 – 2005)
Member, NIH Hematopoietic Stem Cell Transplantation Interest Group (2002 – present)
Reviewer, NCI Medical Oncology Clinical Research Unit Protocol Review Committee (2003 – 2005)
Member, NIH Blood and Marrow Transplant Consortium (2003 – present)
Member, NCI CCR Immunology Faculty (2003-2005)
Member, 3NE Partners Group (2004 – present)
Consultant, Oncologic Drug Advisory Committee, FDA – May 3, 2004
Member, Edmond J. Safra Family Lodge Operations Committee (2004–2005)
Chairman, LTIB Senior Clinician Search Committee (2005)
Member, NCI CCR MOB Branch Chief Search Committee (2005-2006)
Member, Advisory Group for Patient Recruitment Project (2004-2006)
Chairman, Medical Oncology Clinic Committee (2006-present)
Member, NIH Clinical Center Operational Review of Department of Transfusion Medicine (2007-present)
Chairman, Search Committee for NCI CCR MOB for Tenure-Track Position in Breast Cancer Research (2007- 2008)
Member, NCI CCR Grand Rounds Planning Committee for 2007-2008 (2007)
Reviewer, NCI Clinical Investigator Development Program (2008, 2009)
Chairman, Search Committee for Staff Scientist in the Laboratory of Tumor Immunology and Biology, NCI CCR (2008)
Member, NCI Center for Cancer Research Advisory Board (2008-present)
Member, NCI Center for Cancer Research Clinical Tenure Review Panel (2009-present)
Member, NCI Center for Cancer Research Evaluation and Metrics Working Group (2009-present)
Chairman, Search Committee for Tenure-track Investigator in the Laboratory of Tumor Immunology and Biology, NCI CCR (2009)
Member, NCI Clinical Research subcommittee to select Stadtman Investigators (2009)
Member, Search Committee for Tenure-track Investigator in the Dermatology Branch, NCI CCR (2010)

Medical College of Wisconsin Assignments and Committees

Member, MCW Immunotherapy Interest Group (2011-present)
Member, Chief of Hematology/Oncology Search Committee (2011-2012)
Member, American Cancer Society Pilot Research Grant Review Committee (2011)

Mentoring:

Fellow Training:

- 1994-1995 -----(b)(6)-----
 Senior Fellow in Bone Marrow Transplantation
 University of Nebraska Medical Center
 Current position: ---(b)(6)---, Department of Oncology University of
 Navarra, Pamplona, Spain

- 1994 -1996 -----(b)(6)-----
 Fellow in Oncology/Hematology
 University of Nebraska Medical Center
 Current position: -----(b)(6)-----
 -----, National, Cancer Institute/NIH, Bethesda, MD

- 2002-2005 -----(b)(6)-----
 Fellow in Medical Oncology
 National Cancer Institute
 Current position: Assistant Professor of Medicine Cleveland Clinic,
 Cleveland, OH

- 2004 - 2007 -----(b)(6)-----
 Senior Fellow in Medical Oncology
 National Cancer Institute
 Current position: Staff Clinical Scientist, -----(b)(6)-----
 -----, National Cancer Institute/NIH, Bethesda, MD

- 2006 – 2007 -----(b)(6)-----
 Resident, Internal Medicine
 George Washington University Resident (clinical research project)
 Current position: Fellowship in Hematology/Oncology, University of
 Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

- 2009 - 2011 -----(b)(6)-----.
 --- (b)(6) --- Fellow in Medical Oncology
 National Cancer Institute
 Current position: Clinical Investigator, -----(b)(6)-----
 -----, National, Cancer Institute/NIH, Bethesda, MD

Faculty Research Mentorship:

2011 – present -----(b)(6)-----
 -----(b)(6)-----
 Member, Children's Specialty Group
 Medical College of Wisconsin
 Milwaukee, Wisconsin 53226

Graduate Education Faculty Committees:

1995-1996 -----(b)(6)-----
 Member, Graduate Faculty Committee (University of Nebraska
 Medical Center)

1997-1998 -----(b)(6)-----
 Mentor and member, Graduate Faculty Committee (University of
 Nebraska Medical Center)

2003 – 2005 -----(b)(6)-----
 Mentor (clinical) and member, Graduate Faculty Committee for NIH-
 Duke Training Program in Clinical Research

NIH Teaching Activities:

1999 – 2011 Attending, inpatient Hematopoietic Stem Cell Transplantation Service (2
 – 3 months per year).
 2004 - 2011 Attending, inpatient Medical Oncology Solid Tumor Service (2 weeks
 per year).
 1999 – 2011 Attending, Medical Oncology Clinic (2 days per week).
 1999 – 2011 Specialty lecture, “Acute Myelogenous Leukemia” for NHLBI/NCI
 Hematology Lecture Series (once per year).
 1999 – 2000 Specialty lecture, "Autologous Stem Cell Transplantation" for
 NHLBI/NCI lecture series (once per year).
 1999 – 2003 Specialty lecture, “Alternative Donors in Hematopoietic Stem Cell
 transplantation” for NHLBI/NCI Hematology Lecture Series (once per
 year).
 1999 – 2011 Medical Oncology Fellows Journal Club (once per year).
 2001 – 2002 Specialty lecture to Medical Oncology Fellows on “Monoclonal
 Antibodies”, (two per year).
 2001 – 2011 Specialty lecture to Medical Oncology Fellows on “Role Stem Cell
 Transplantation for Breast Cancer”, (two per year).
 2003 Specialty lecture, “Bone Marrow Transplantation” for NCI CCR
 Translational Research in Clinical Oncology.
 2006 – 2011 Specialty lecture to Medical Oncology, “Overview of HLA and
 Allogeneic Donor Types, Sources, and Selection” (8 – 10 per year).

Medical College of Wisconsin Teaching Activities

2011 – present	Specialty lecture to Hematology-Oncology Fellows, “Chronic Lymphocytic Leukemia”
2011 – present	Specialty lecture to Hematology-Oncology Fellows, “Follicular Lymphoma”
2011 – present	Attending, inpatient Hematopoietic Stem Cell Transplantation Service (4 weeks per year).
2011 - present	Attending, inpatient Hematologic Malignancies Service (4 weeks per year).

Extramural Teaching Activities:

Extramural Lectures in Team-Taught Courses (University of Nebraska Medical Center):

11/09/95	Advanced Hematology Course - "Myelodysplastic Syndrome"
11/13/95	Transplantation – Allogeneic
1/04/96	Winter Workshop III preceptor for students from Chadron and Wayne State College
1995-1998	Family Practice Review - “Evaluation of Anemia”

Residency Related Teaching Activities (University of Nebraska Medical Center)

1996	Lecture for Histocompatibility Study Group
1995, 1996	Annual Internal Medicine Resident Noon Conferences "Acute and Chronic Leukemias" 1995 & 1996
1995 – 1999	Core Lectures in Oncology/Hematology - Resident Lectures (1.0 hours) given on a semi-monthly basis: "Principles of Chemotherapy" "Principles of Bone Marrow Transplantation" "Acute Leukemia" "Stem Cells"

Residency/Fellowship Related Teaching Activities (Medical College of Wisconsin)

2011	Fellowship core lecture series – “Chronic Lymphocytic Leukemia”
2011	Fellowship core lecture series – “Follicular Lymphoma”

Grant Review:

- NOT-AI-04-044 Biodefense Countermeasure Development: Project Bioshield, HHS/NIH/NIAID. (November 2004)
- Grant Application Review Panel for the FDA Office of Orphan Products Development, (March 2005)
- NIH Director’s New Innovator Award (July 2007)
- ZRG1 Onc-B, Cancer and Immunology, Center for Scientific Review, NIH (October 2007)

Community Service:

Board Member, Nebraska Chapter of Leukemia Society of America,
 National representative, Leukemia Society of America (1996-1999)
 Scientific Advisor, Men Against Breast Cancer (1999-2002)
 Faculty, National Breast Cancer Coalition, 1999
 Board Member, Medical Advisory Committee, National Capitol Area of The Leukemia & Lymphoma Society (2004 – 2007)
 - Leukemia & Lymphoma Society Patient Education Program – “Transplant Options for Patients with Multiple Myeloma”, January 18, 2005, Fairfax, Virginia
 - Leukemia & Lymphoma Society Patient Education Program - “Non-Hodgkin’s Lymphoma”, October 17, 2005, Fairfax, Virginia
 Script consultant (through NCI Office of Communication) to The Norman Lear Center USC Annenberg School for Communication (2004 – 2011)

Extramural Faculty Activities:

National Marrow Donor Program, Donation Center Director, University of Nebraska Medical Center (1994-1999)
 Institutional Director, International Bone Marrow Transplantation Registry, University of Nebraska Medical Center (1992 – 1999)
 Director, Leukemia Program and Allogeneic Bone Marrow Transplantation, University of Nebraska Medical Center (1992-1999)

Patents

------(b)(4)-----

 -----.

Selected Invited Presentations (since 1999):

1. “Graft-vs-Host Disease”, Temple University Hospital, Philadelphia, Pennsylvania, February 11, 1999.
2. “Clinical Results of Allogeneic Blood Stem Cell Transplantation at UNMC”, University of Nebraska Medical Center Allogeneic Stem Cell Conference, Omaha, Nebraska, March 19, 1999.
3. “Graft-vs-Host Disease: Diagnosis and Treatment”, Medical Grand Rounds at Loyola University - Stritch School of Medicine, Chicago, Illinois, March 30, 1999.
4. “Allogeneic Stem Cell Transplantation”, University of Nebraska Medical Center Internal Medicine Grand Rounds, Omaha, Nebraska, April 9, 1999.
5. “Critical Issues in Allogeneic Stem Cell Transplantation”, 7th International Symposium - Recent Advances in Hematopoietic Stem Cell Transplantation - University of California (UCSD), San Diego, California, May 6 - 8, 1999.

6. "The Role of Clinical Trials in Blood and Marrow Transplantation", The Evolving Role of Blood and Marrow Transplantation – United Resource Networks, Naples, Florida, January 24, 2000
7. "Lymphomas – What's New?" – Update on Hematologic Malignancies and Multiple Myeloma – The Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences, Little Rock, AR, March 17-18, 2000
8. "Overview of Chronic Graft-versus-Host Disease". – Emerging Strategies in the Treatment of Chronic Graft-versus-Host Disease, 2001 Tandem Transplant Meetings, Keystone, Colorado, February 26, 2001
9. "Non-myeloablative Allogeneic Stem Cell Transplantation", Moffitt Cancer Center Grand Rounds, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, March 23, 2001
10. "Hematologic Reconstitution After Allogeneic PBPC Transplantation", The Evolving World of Cellular Support – 27th Annual Meeting European Group for Blood and Marrow Transplantation, Maastricht, The Netherlands, March 25, 2001
11. "Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer", 21st Annual Symposium: Immunohematology and Blood Transfusion, Bethesda, MD, September 26, 2002
12. "Non-myeloablative Allogeneic stem Cell Transplantation for Non-Hodgkin's Lymphoma", Innovations in Lymphoma Treatment – Lymphoma Research Foundation, Chicago, IL, June 15, 2002
13. "Submyeloablative Allogeneic Stem Cell Transplantation in Breast Cancer", Future of Breast Cancer: An International Breast Cancer Symposium, Paradise Islands, the Bahamas, July 31-August 3, 2002
14. "Experimental Model of Transplantation", Cleveland Clinic Cancer Center grand Rounds, Cleveland, OH, November 15, 2002
15. "Blood and Marrow Transplantation for Low Grade and Mantle Cell Lymphomas", United Resource Networks 5th Annual Evolving Science of Blood/Marrow Transplantation Conference, New Orleans, LA, March 12-14, 2003
16. "Reduced Intensity Allogeneic hematopoietic Stem Cell Transplantation", 5th NCI/CCR Annual Symposium for Practicing Physicians, Bethesda, MD, May 10, 2003
17. "Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Solid Tumors", Educational Session, 2003 Annual Meeting of American Society of Clinical Oncology, Chicago, IL, May 31 – June 4, 2003
18. "Adoptive Immunotherapy for Malignant Disease", American Society of Clinical Oncology Annual Meeting Educational Session, Chicago, IL, May 31 – June 4, 2003
19. "But Doctor, What Have I Got to Lose....", A Research Clinician's Perspective of Phase I Trials", Patient Advocate Foundation, Patient Congress IV, Washington, DC, June 4-6, 2003
20. "Stem Cell Transplantation: Promise in Cancer Treatments and Blood Disorders", NIH Clinical Center 2003 Medicine for the Public Series, Bethesda, MD, October 7, 2003
21. "Tumor Lysis Syndrome", Washington Hospital Center, Washington, D.C., February 27, 2004
22. "Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma", Georgetown University Hospital BMT Conference, Georgetown University Hospital, Washington, D.C., April 15, 2004

23. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic breast Cancer", First Annual John Laws Decker Memorial Lecture, NIH Clinical Center, National Institutes of Health, Bethesda, MD, June 2, 2004
24. "Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center's Hematology/Medical Oncology Board Review Course, Alexandria, Virginia, October 6 - 13, 2004
25. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic Breast Cancer", 8th Annual Meeting of the Regional Cancer Center Consortium for the Biological Therapy of Cancer, Hershey, PA, February 24-26, 2005
26. "Factors Affecting Full Donor Engraftment of Allogeneic Hematopoietic Stem Cells after Reduced-Intensity Conditioning", NIH Workshop for Hematopoietic Cell Transplantation for Autoimmune Disease, Bethesda, MD, March 13, 2005
27. "Tumor Antigen Immunization of Human Allograft Donors in Myeloma", 10th International Myeloma Workshop, Sydney, Australia, April 10-14, 2005
28. "Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma", Hematology-Oncology Conference, Howard University Medical Center, Washington, D.C., August 26, 2005
29. "Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center's Hematology/Medical Oncology Board Review Course, Alexandria, Virginia, September 21 - 28, 2005
30. "Allogeneic T Cells as Adoptive Immunotherapy for Metastatic Breast Cancer", 2nd ASCT Meeting - Allogeneic Transplantation in Solid Tumors, Stresa-Lago Maggiore, Italy, October 7-8, 2005
31. "Immunotherapy", Mount Vernon Hospital grand Rounds, Mount Vernon, Virginia, October 25, 2005
32. "Treatment of Lymphoma", Doctors Community Hospital Grand Rounds, Lanham, Maryland, February 9, 2006
33. "Adoptive Cellular Therapy", Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, February 21, 2006
34. "Hematopoietic Stem Cell Transplantation for Hematologic Malignancies", Hematology-Oncology Conference, Walter Reed Army Medical Center, Washington, D.C., March 8, 2005
35. "Increasing Indications for Allogeneic Hematopoietic Stem Transplantation", Educational Session, 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, June 5, 2006
36. "Diagnostic & Therapeutic Options for Non-Hodgkin's Lymphoma", Nova Fairfax Hospital, Fairfax, Virginia, September 19, 2006
37. "T-cell Depletion and Host Immune Reconstitution after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation", 2nd Annual Frontiers of Clinical Investigation: Bench to Bedside Symposium (co-sponsored by Nature Medicine and the UCSD Clinical Investigation Institute), La Jolla, California, October 5-7, 2006
38. "Targeted Therapies - Vaccines, Stem Cell Transplantation and Novel Approaches", Oncology Update 2006: Treatment Advances for breast Lung and Colon Cancer, Saint Agnes Medical Center, Fresno, California, October 7, 2006 (Keynote speaker).

39. "Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center's Hematology/Medical Oncology Board Review Course, Arlington, Virginia, October 4-8, 2006
40. "Hematopoietic Stem Cell Transplantation for Cutaneous T-cell Lymphoma", NCI CTCL Interest Group, Bethesda, MD, November 20, 2006
41. "Non-Myeloablative Hematopoietic Stem Cell Transplantation", International Society for Cutaneous Lymphoma, Washington, DC, February 1, 2007
42. "The Role of Stem Cell Transplantation in Lymphoma Therapy", Washington Hospital Center, Washington, DC, March 23, 2007
43. "Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma", M.D. Anderson Cancer Center, Houston, TX, April 18, 2007
44. "Organizational Structure of Medical Oncology in the United States", Clinical Oncology in Croatia - Strategic planning and Beyond, Zagreb, Croatia, May 11-13, 2007
45. "Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center's Hematology/Medical Oncology Board Review Course, Washington, DC, September 29 – October 3, 2007
46. "Novel Approaches to Allogeneic Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center, Washington, DC, January 30, 2009
47. "Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia", Washington Hospital Center, Washington, DC, February 6, 2009
48. "Novel Approaches to Allogeneic Hematopoietic Stem Cell Transplantation", Walter Reed Army Medical Center, Washington, DC, March 20, 2009
49. "Hematopoietic Stem Cell Transplantation: A Field in Transformation", NCI Center for Cancer Research Grand Rounds, National Cancer Institute, Bethesda, MD, March 31, 2009
50. "Biology and Treatment of Relapsed Malignancy Following Allogeneic Stem Cell Transplantation", Cancer Center Grand Rounds, Hackensack University Medical Center, Hackensack, NJ, May 19, 2009
51. "Hematopoietic Stem Cell Transplantation", The George Washington University Medical Center's Hematology/Medical Oncology Board Review Course, Washington, DC, October 13-15, 2009
52. "Targeted Lymphocyte-depleting Chemotherapy And Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation Using Volunteer Matched Unrelated Donors And Unrelated Cord Blood Units", HSCT Interagency Workgroup Meeting - Health Resources and Services Administration, Bethesda, MD, October 22, 2009
52. "How to Treat Lymphoma Relapsing After Hematopoietic Cell Transplantation (Meet the Experts)", 51st ASH Annual Meeting and Exposition, New Orleans, LA, December 5-8, 2009
53. "Strategies For Treatment Of Relapse After Allogeneic Transplantation", Experimental Transplantation and Immunology Branch Scientific Seminar, National Cancer Institute, Bethesda, MD, January 13, 2010
54. "Relapse After Allogeneic Hematopoietic Cell Therapy", 2010 BMT Tandem Meetings, Orlando, Florida, February 28, 2010
55. "Emerging Therapies in Oncology: Matched Unrelated Donor Transplantation", Advanced Oncology Education Series, National Institutes of Health, Bethesda, MD, March 24, 2010
56. "Allogeneic Cellular Therapies for B-cell Malignancies", University of Louisville Hematology Grand Rounds, Louisville, KY, April 16, 2010

57. "CQ-Roll Call Forum on the Future of Blood and Marrow Transplant Research", National Marrow Donor Program, Washington, DC, April 22, 2010
58. "Allogeneic Cellular Therapies for B-cell Malignancies", Rush University Cancer Center Grand Rounds, Chicago, IL, April 29, 2010
59. "Hematopoietic Stem Cell Transplantation", The George Washington University Hematology Oncology Best Practices 2010, Washington, DC, September 29-30, 2010
60. "Post HCT Relapse Treatment Strategies", BMT Tandem Meetings Clinical Practice Forum, Honolulu, Hawaii, February 19, 2011
61. "Summary of the NCI 1st International Workshop on the Biology, Prevention and Treatment of Relapse after HCT", 2011 BMT Tandem Meetings, Honolulu, Hawaii, February 17-21, 2011
62. "Clinical Trials", The Leukemia & Lymphoma Society, Suburban Hospital, Bethesda, MD, March 24, 2011
63. "Anything New in the Prevention or Treatment of Relapse after Allogeneic HCT?" Leukemia and Lymphoma - East and West Are Together (in conjunction with) New Trends in the Treatment of Acute Leukemia, Dubrovnik, Croatia, September 16-20, 2011
64. "Recent Advances in the Treatment of Non-Hodgkin's Lymphoma", Medical College of Wisconsin Advances in Hematology & Oncology Series, Milwaukee, WI, September 28, 2011
65. "Myeloma for Non-beginners", 9th Annual Multiple Myeloma Conference Emerging Therapies: Strengthening Hope, Milwaukee, WI, October 1, 2011
66. "Recent Advances in the Treatment of Non-Hodgkin's Lymphoma", Medical College of Wisconsin Advances in Hematology & Oncology Series, Green Bay, WI, January 17, 2012
67. "Prevention Of Relapse Following Allogeneic HCT In Adult Patients With Myeloid Malignancies", 2012 BMT Tandem Meetings, San Diego, CA, February 1-5, 2012
68. "Adoptive Immunotherapy for Hematologic Malignancies: Dawn of a New Era", Medical College of Wisconsin Medical Grand Rounds, Milwaukee, WI, February 17, 2012

Publications:

1. Messmore HL, **Bishop MR**, Wehrmacher WH. Acute venous thrombosis: Therapeutic choices for superficial and deep veins. *Postgraduate Medicine* 89:73-77, 1991 (invited review).
2. Stiff PJ, Schulz WC, **Bishop MR**, Marks L. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification bone marrow in acute non-lymphocytic leukemia. *Blood* 77:355-362, 1991.
3. **Bishop MR**, Bierman PJ, Vose JM, and Armitage JO. The Role of High-Dose Therapy With Hematopoietic Stem Cell Rescue in Low-Grade Non-Hodgkin's Lymphoma. *Annals of Oncology* 4(suppl 1):1-6, 1993.
4. **Bishop MR**. Discovery--And Implications--Of a Single Human Bone Marrow Stem Cell. *Oncology Bulletin* 16:2, 1993.
5. Bayever E, Iversen PL, **Bishop MR**, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Rudson RW, Kessinger A, Zon G and Armitage JO. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. *Antisense Research and Development*, 3:383-390, 1993.
6. Kessinger A, Vose JM, Bierman PJ, **Bishop MR**, Armitage JO. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. *Journal of Hematotherapy* 2:361-2, 1993.
7. **Bishop MR**, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose JV, Armitage JO, Warkentin PI, Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. *Blood* 83:610-616, 1994.
8. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, **Bishop MR**, Armitage JO. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. *Semin Hematol* 31(Suppl 3):4-8, 1994.
9. Armitage JO, Vose JM, Bierman PJ, **Bishop MR**. Salvage therapy for patients with lymphoma. *Seminars in Oncology*, 21(Suppl 7):82-5, 1994.
10. **Bishop MR**, Bierman PJ, Vose JM, and Armitage JO. Non-Hodgkin's Lymphoma and Autologous Stem Cell Transplantation: A Critical Review. *Revisions en Cáncer*, 8:158-164, 1994.
11. **Bishop MR**, Warkentin PI, Jackson JD, Bayever E, Iversen PL, Whalen VI, Lastovica J, Haines K, Kessinger A. Antisense oligonucleotide OL (1)P53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. *Prog Clin Biol Res* 389:183-7, 1994.
12. Jackson JD, Letheby B, O'Kane Murphy B, Costas P, Wang PN, **Bishop MR**, Kessinger A, Warkentin PI. Kinetics of low and high dose granulocyte/macrophage colony stimulating factor mobilization of peripheral blood stem cells. *Prog Clin Biol Res* 389:471-7, 1994.
13. Kessinger A, Vose JM, Bierman PJ, **Bishop MR**, and Armitage JO. Peripheral blood stem cell transplantation in malignant lymphomas. *Hem Onc Annals* 3:47-52, 1994.
14. Kessinger A, Armitage J, Bierman P, **Bishop M**, Joshi S, Reed E, Sharp G, Talmadge J, Vose J. Clinical outcome of peripheral blood stem cell support. *Medical Oncology* 11:43-46, 1994.

15. Darrington DL, Vose JM, Anderson JR, Bierman PJ, **Bishop MR**, Chan WC, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Morris ME, Kessinger A, Armitage JO. Incidence and Characterization of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia Following High-Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for Lymphoid Malignancies. *J Clin Oncol* 12:2527-34, 1994.
16. **Bishop MR**, Armitage JO. Cytokine therapy in bone marrow transplantation. *Advances in the Biosciences* 94:15-20, 1994.
17. Armitage JO, Bierman PJ, Vose JM, **Bishop MR**, Kessinger MA. Autologous bone marrow transplantation for Hodgkin's disease. *J Hematotherapy* 4:61-2, 1995.
18. Kessinger A, **Bishop MR**, Anderson J, Armitage JO, Bierman PJ, Reed E, Tarantolo S, Tempero M, Vose JM, and Warkentin PI. A comparison of subcutaneous and intravenous administration of rhGM-CSF for peripheral blood stem cell mobilization. *J Hematotherapy*. 4:81-4, 1995.
19. Kessinger A, **Bishop MR**, Jackson JD, O'Kane-Murphy B, Vose JM, Bierman PJ, Reed EC, Warkentin PI, Armitage JO, Sharp JG. Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. *Exp Hematol* 23:609-12, 1995.
20. Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ, Whalen VL, **Bishop MR**. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. *Leukemia Lymphoma* 20:67-76, 1995.
21. Martin-Algarra S, **Bishop MR**, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, and Kessinger A. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. *Experimental Hematology* 23:1503-08, 1995.
22. Sharp JG, **Bishop MR**, Chan WC, Greiner T, Joshi SS, Kessinger A, Reed E, Sanger W, Tarantolo S, Traystman M, et-al. Detection of minimal residual disease in hematopoietic tissues. *Ann New York Acad Sci* 770:242-61, 1995.
23. Joshi SS, Wu AG, Verbik DJ, Algarra SM, **Bishop MR**, Pirruccello SJ, Iversen PL, Jackson JD, Kessinger MA, Sharp JG. Oligonucleotides complementary to c-myc messenger RNA inhibit growth and induce apoptosis in human Burkitt Lymphoma cells. *International Journal of Oncology* 8:815-20, 1996.
24. **Bishop MR**, Iversen PL, Bayever E, Sharp JG, Greiner TC, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, and Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. *J Clin Onc* 14:1320-6, 1996.
25. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, **Bishop MR**, Armitage JO. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. *Ann Oncology* 7:151-156, 1996.
26. Pavletic ZS, **Bishop MR**, Bierman PJ, Armitage JO. Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. *Biomedicine Pharmacotherapy* 50:118-24, 1996.
27. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E, Munn RK, Messino MJ, Macdonald JS, **Bishop M**, Rayens MK, Thompson JS, Foon KA. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. *Bone Marrow Transplant* 17:917-22, 1996.

28. Pavletic ZS, **Bishop MR**, Markopoulou K, and Wszolek ZK. Drug-induced Parkinsonism after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 17:1185-7, 1996.
29. Vose JM, Bierman PJ, Ruby E, Reed EC, **Bishop MR**, Tarantolo S, Kessinger A, and Armitage JO. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. *Bone Marrow Transplant* 17:951-6, 1996.
30. **Bishop MR**, Jackson JD, O'Kane-Murphy B, Schmit-Pokorny K, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Garrison L, and Kessinger A. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. *J Clin Oncol* 14:2521-6, 1996.
31. Bennett CL, **Bishop MR**, Gulati SC. Economic implications of high dose chemotherapy programs with autologous stem cell support. *Proc Molecular Biol Hematopoiesis*, 5:45-52, 1996.
32. **Bishop MR**, Henslee-Downey PJ, Anderson JR, Romond EH, Marciniak E, Yankey R, Reeves M and Thompson JS. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. *Bone Marrow Transplant* 18:747-53, 1996.
33. O'Donnell MR, Appelbaum F, **Bishop MR**, Estey EH, Grever M, Maslak P. NCCN Acute Leukemia Practice Guidelines. The National Comprehensive Cancer Network. *Oncology* 10(11 Suppl):205-21, 1996.
34. Bierman PJ, Vose JM, Anderson JR, **Bishop MR**, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. *J Clin Oncol* 15:445-50, 1997.
35. **Bishop MR**, Kessinger A. Blood stem cell transplantation in non-hodgkin's lymphoma. *Cancer Invest* 15:138-42, 1997 (invited review).
36. **Bishop MR**, Tarantolo SR, Jackson JD, Anderson JR, Schmit-Pokorny K, Zacharias D, Pavletic ZS, Pirruccello SJ, Vose JV, Bierman PJ, Warkentin PI, Armitage JO, Kessinger A. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. *J Clin Oncol* 15:1601-07, 1997.
37. Pavletic ZS, **Bishop MR**, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TJ, Kollath J, Nasrati K, Jackson JD, Armitage JO, Kessinger A. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. *J Clin Oncol* 15:1608-16, 1997.
38. **Bishop MR**. Potential use of hematopoietic stem cells after radiation injury. Radiation Injury and the Chernobyl Catastrophe. *Stem Cells* 15(suppl 2): 305-10, 1997.
39. Benner E, **Bishop MR**, Agarwal N, Iversen P, Joshi SS. Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies. *J Pharmacological and Toxicological Methods* 37:229-35, 1997.
40. **Bishop MR**, Jackson JD, Tarantolo SR, O-Kane-Murphy B, Iversen PL, Bayever E, Joshi SM, Sharp JG, Pierson JL, Warkentin PI, Armitage JO, Kessinger A. Ex Vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. *J Hematotherapy* 6:441-46, 1997.
41. Rao AK, Kuszynski CA, Benner E, **Bishop MR**, Jackson JD, Iversen PL, Joshi SS. Increased growth inhibition of human chronic myelogenous leukemic cells by a combination

- of c-myb antisense oligonucleotide and 4-hydroxperoxycyclophosphamide in vitro. *Int J Oncol*, 11:281-287, 1997.
42. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K, Armitage JO, Kessinger A, **Bishop MR**. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. *Bone Marrow Transplant* 21:33-41, 1998.
 43. Gross TG, Hinrichs MD, Davis JR, Mitchell D, **Bishop MR**, Wagner JE. Depletion of (EBV) infected cells in donor marrow by counterflow elutriation. *Exp Hematol* 26:395-9, 1998.
 44. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, **Bishop MR**, Chaekal O, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JMM, Reiffers J, Phillips GL, Schattenberg AVMB, Verdonck LF, Vose JM, Horowitz MM. Allogeneic Bone Marrow Transplantation For Low Grade Lymphoma. *Blood* 92:1832-6, 1998.
 45. Kessinger A, Bierman PJ, Cowles MK, Anderson JR, Armitage JO, **Bishop MR**, Vose JM. Mobilized Versus Non-Mobilized Peripheral Stem Cell Transplantation After High Dose Therapy for Low Grade Nonhodgkin Lymphoma. *Cancer Res Ther Control*, 5:113-9, 1998.
 46. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR, Kuszynski CA, Pirruccello SJ, **Bishop MR**, Kessinger A. Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. *Int J Oncol* 13:791-799, 1998.
 47. Pavletic ZS, Bierman PJ, Vose JM, **Bishop MR**, Wu CD, Pierson JL, Kollath JP, Weisenburger DD, Kessinger A, Armitage JO. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. *Ann Oncol* 9:1023-6, 1998.
 48. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K, Armitage JO, Kessinger A, **Bishop MR**. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies *Bone Marrow Transplant* 21:33-41, 1998.
 49. Haire WD, Ruby EI, Stephens LC, Reed E, Tarantolo SR, Pavletic ZS, Bierman PJ, **Bishop MR**, Kessinger A, Vose J, Armitage JO. A Prospective, Randomized, Double-Blind Trial of Antithrombin III Concentrate in the Treatment of Multiple Organ Dysfunction Syndrome During Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 4:142-50, 1998.
 50. **Bishop MR**. The risk of secondary leukemias following autologous stem cell transplantation. Commentary on the paper by G Lambertenghi Delilieri et al. Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantations. *Leukemia Res* 23:281-2, 1999.
 51. Greengerg P, **Bishop MR**, Deeg J, Estey E, Erba H, Gore S, Nimer S, O'Donnell M, Stone R, Tallman M, Bennett J. NCCN Practice Guidelines for the Myelodysplastic Syndromes. *Oncology* 12:53-80, 1998.
 52. Brand RE, DiBaise JK, Quigley EMM, Gobar LS, Harmon KS, Lynch JC, Bierman PJ, **Bishop MR**, Tarantolo SR. Gastroparesis as a cause of nausea and vomiting after high dose chemotherapy and haemopoietic stem-cell transplantation. *Lancet* 352:1985, 1998.
 53. Iwen PC, Rupp ME, **Bishop MR**, Rinaldi MG, Sutton DA, Tarantolo S, Hinrichs SH. Disseminated Aspergillosis Caused by *Aspergillus ustus* in a Patient Following Allogeneic Peripheral Stem Cell Transplantation. *J Clin Microbiol* 36:3713-17, 1998.

54. **Bishop MR.** Alternative Donor Sources in Allogeneic Stem Cell Transplantation. *Medscape Oncology* 1(6), 1998. (online publication)
55. Pavletic ZS, Bierman PJ, Vose JM, **Bishop MR**, Wu CD, Pierson JL, Kollath JP, Weisenburger DD, Kessinger A, Armitage JO. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. *Ann Oncol* 9:1023-6, 1998.
56. Freeman M, Vose J, Bennett C, Anderson J, Kessinger A, Turner K, Pierson J, **Bishop M**, Bierman P, Armitage J. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. *Bone Marrow Transplant* 24:679-84, 1999.
57. Pirruccello SJ, Page CJ, **Bishop MR**, Letheby BA, Warkentin PI, Jackson JD, Kessinger A. Comparison of ISHAGE Protocol CD34 Cell Enumeration with a Lineage Negative Backgating Technique. *Cytotherapy* 1:279-86, 1999.
58. Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S, **Bishop M**. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant* 24:555-60, 1999.
59. Bennett CL, **Bishop MR**, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. *Ann Oncol* 10:1355-9, 1999.
60. Gordon B, Lyden E, Lynch J, Tarantolo S, Pavletic ZS, **Bishop M**, Reed E, Kessinger A, Haire W Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients. *Bone Marrow Transplant* 25:79-83, 2000.
61. Bennett CL, Stinson TJ, Laver JH, **Bishop MR**, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making? *Leuk Lymphoma*. 37:65-70, 2000.
62. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, Kollath JP, Weisenberger DD, Kessinger A, Wolff SN, Armitage JO, **Bishop MR**. Outcome of allogeneic stem cell transplantation for B-CLL chronic lymphocytic leukemia. *Bone Marrow Transplant* 25:717-22, 2000.
63. **Bishop MR**, Tarantolo SR, Pavletic ZR, Lynch JC, Morris ME, Zacharias D, Armitage JO, Kessinger A. Filgrastim as an alternative to donor leukocyte infusion for relapse following allogeneic stem cell transplantation. *J Clin Oncol* 18:2269-72, 2000.
64. **Bishop MR**, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Z. Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A. A randomized double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. *Blood* 96:80-4, 2000.
65. Stinson TJ, Adams JR, **Bishop MR**, Kruse S, Tarantolo S, Bennett CL. Economic Analysis of a Phase III Study of G-CSF versus Placebo Following Allogeneic Blood Stem Cell Transplantation. *Bone Marrow Transplant* 26:663-6, 2000.
66. Mata JE, Jackson JD, Joshi SS, Tracewell WG, Pirruccello SJ, Murphy BJ, **Bishop MR**, Iversen PL. Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine. *J Hematotherapy* 9:205-14, 2000.

67. Mata JE, **Bishop MR**, Tarantolo SR, Angel CR, Swanson SA, Iversen PL. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. *J Toxicol Clin Toxicol* 38:383-7, 2000.
68. McCarthy NJ, **Bishop MR**. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. *Oncologist* 5:487-96, 2000 (invited review).
69. Sharp JG, **Bishop MR**, Iversen PL. Oligonucleotide enhanced cytotoxicity of idarubicin for lymphoma cells. *Leukemia Lymphoma* 42:417-27, 2001.
70. **Bishop MR**. Non-myeloablative allogeneic stem cell transplantation as adoptive cellular therapy. *Principle Practice Biologic Ther Cancer* 2:1-9, 2001 (invited review).
71. Joshi SJ, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A, **Bishop MR**. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. *Blood* 98:1963-70, 2001.
72. Weisdorf D, **Bishop M**, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, Horowitz M. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. *Biol Blood Marrow Transplant* 8:213-20, 2002.
73. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, **Bishop MR**. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. *Bone Marrow Transplant* 29:709-710, 2002.
74. Khuu HM, Cowley H, David-Ocampo V, Carter CS, Kasten-Sportes C, Wayne AS, Solomon SR, **Bishop MR**, Childs RM, Read EJ. Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences. *Cytotherapy* 4:539-49, 2002.
75. Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read E, Gea-Banacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June C, Gress R, **Bishop M**. Phase I clinical trial of donor T-helper Type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. *Cytotherapy* 4:429-30, 2002.
76. Knutson KL, **Bishop MR**, Schiffman K, Disis ML. Immunotherapy for breast cancer. *Cancer Chemother Biol Response Modif.* 20:351-69, 2002 (invited review).
77. **Bishop MR**, Whit-Shan Hou J, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, and Fowler DH. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. *Biol Blood Marrow Transplant* 9:162-9, 2003.
78. Navolanic PM, Pui CH, Larson RA, **Bishop MR**, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek(TM)-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. *Leukemia* 17:499-514, 2003.
79. **Bishop MR**. Non-myeloablative allogeneic stem cell transplantation for breast cancer. *Clinical Breast Cancer* 4:39-45, 2003.
80. Dean RM, Bishop MR. Graft-versus-host disease: emerging concepts in prevention and therapy. *Curr Hematol Rep* 2:287-94, 2003 (invited review).
81. **Bishop MR**. Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity? *J Clin Oncol* 21:3713-5, 2003. (editorial)

82. Joshi S, **Bishop M**, Lynch J, Tarantolo S, Abhyankar S, Bierman P, Vose J, Geller R, McGuirk J, Foran J, Bociek R, Hadi A, Day S, Armitage J, Kessinger A, Pavletic Z. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. *Cytotherapy* 5:542-52, 2003.
83. **Bishop MR**. The evolution of hematopoietic stem cell transplantation for multiple sclerosis. *Blood* 102:2314, 2003. (editorial)
84. Fowler DH, **Bishop MR**, Gress RE. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. *Sem Oncol* 31:56-67, 2004.
85. Kwak LW, Neelapu SS, **Bishop MR**. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. *Semin Oncol* 31:37-46, 2004. (invited review)
86. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, Fowler DH, **Bishop MR**, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs R, Illie GG, Leitman SF, Malech HL, Horwitz ME. Severe Chronic Graft-Versus-Host Disease is Characterized by a Preponderance of CD4+ Effector Memory Cells Relative to Central Memory Cells. *Blood* 103:2973-80, 2004.
87. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, **Bishop MR**, Childs R, Barrett AJ, Csaky KG. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. *Bone Marrow Transplant* 33:1031-5, 2004.
88. Dean RM, **Bishop MR**. Allogeneic stem cell transplantation in non-Hodgkin's lymphoma. *Clin Lymphoma* 4:238-49, 2004. (invited review).
89. **Bishop MR**. Allogeneic hematopoietic stem cell transplantation for breast cancer. *Haematologica* 89:599-605, 2004. (invited review)
90. Fowler DH, Foley JE, Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, **Bishop MR**. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: Correlation of TNF-alpha with severe gut graft-versus-host disease. *Clin Gastro Hepatology* 2:237-45, 2004.
91. **Bishop MR**, Steinberg SM, Marchigiani D, Kasten-Sportes C, Hardy N, Dean R, Castro K, Hakim F, Read EJ, Carter C, Leitman SF, Gress RE, Fowler DH. Ex-vivo T cell depleted allogeneic blood stem cell transplantation after reduced intensity conditioning: effect of host T cell depletion on engraftment. *Br J Haematol* 126:837-43, 2004.
92. **Bishop MR**, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. *J Clin Oncol* 22:3886-92, 2004.
93. Cairo MS, **Bishop MR**. Tumor lysis syndrome. *Br J Haematol* 127:3-11, 2004.
94. Walshe J, **Bishop MR**. Factors that affect engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning. *Cytotherapy* 6:589-92, 2004.
95. Pavletic SZ, Smith LM, **Bishop MR**, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Prognostic Factors of Chronic Graft-versus-host Disease after Allogeneic Blood Stem Cell Transplantation. *Am J Hematol* 78:265-74, 2005.
96. Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummur S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, **Bishop MR**, Fowler DH, Gress RE. Establishing a platform for immunotherapy: Clinical outcome and study of

- immune reconstitution following high-dose chemotherapy with progenitor cell support in breast cancer patients. *Biol Blood Marrow Transplant* 11:472-83, 2005.
97. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, **Bishop MR**. Response to salvage chemotherapy and outcome of reduced-intensity allogeneic stem cell transplantation for non-Hodgkin's lymphoma: chemosensitive disease is not required for durable survival. *Biol Blood Marrow Transplant* 11:593-9, 2005.
 98. Pavletic ZS, Khouri IF, Haagenson M, King RJ, Bierman PJ, **Bishop MR**, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. *J Clin Oncol* 23:5788-94, 2005.
 99. O'Mahoney D, **Bishop MR**. Monoclonal antibody therapy. *Frontiers in Bioscience* 11:1620-35, 2006. (invited review).
 100. Yamashita K, Horwitz ME, Kwatema A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, **Bishop MR**, Childs RW, Barrett AJ, Pavletic SZ, Malech HL. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. *Biol Blood Marrow Transplant* 12(1 Suppl 2):22-30, 2006.
 101. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, **Bishop MR**, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant* 12:204-16, 2006.
 102. Hardy NM, Daniel H, Fowler DH, **Bishop MR**. Immunotherapy of Metastatic Breast Cancer: Phase I Trial of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation with Th2/Tc2 T-Cell Exchange. *Clin Breast Cancer* 7:87-89, 2006.
 103. Bevans M, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P, Mayberry H, **Bishop MR**, Childs R and J Barrett J. Health-Related Quality of Life in Patients Receiving Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. *Bone Marrow Transplantation*, 38:1-9, 2006.
 104. Yao K, Akyani N, Donati D, Sengamalay N, Fotheringham J, Ghedin E, **Bishop M**, Barrett J, Kashanchi F, Jacobson S. Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis. *J Clin Virol* 37(Suppl 1):S57-62, 2006.
 105. Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh U, **Bishop M**, Barrett J, Gea-Banacloche J, Jacobson S. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. *J Infect Dis* 195:450-4. 2007.
 106. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Mair R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, **Bishop MR**. Phase I Clinical Trial of Hematopoietic Stem Cell Allograft Augmentation with Co-stimulated, IL-4 Polarized Donor CD4+ T Cells. *Biol Blood Marrow Transplant* 12:1150-60, 2006.

107. Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu O, Wu T, Barrett AJ, **Bishop MR**, Childs RW, Fowler DH, Pavletic ZS, Thomas C, Hart TC. Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Profound Changes in Salivary Proteome. *Exp Hematol* 35:184-92, 2007.
108. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, **Bishop MR**, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. *Leukemia* 21:169-74, 2007.
109. Nava VE, Cohen P, **Bishop M**, Fowler D, Jaffe ES, Ozdemirli M. Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. *Am J Surg Pathol* 31:476-80, 2007.
110. Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler D, Gress R, **Bishop MR**. Allograft T Cell-Depletion Reveals Host Determinants of Early Donor T cell Engraftment and Recovery after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 13:1022-30, 2007
111. Stratton P, Turner ML, Childs R, Barrett AJ, **Bishop MR**, Wayne A, Pavletic SZ. Vulvo-Vaginal Graft versus Host Disease: an unrecognized problem responsive to topical glucocorticoid and hormone therapy. *Obstet Gynecol* 110:1041-9, 2007
112. Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M, Fontaine LS, Babb R, **Bishop MR**, Caporaso N, Marti GE. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. *Br J Haematol* 139:824-831, 2007
113. **Bishop MR**, Bolwell BJ, Cahn, JY, Gandham S, Giralt S, Horowitz, MM, Keating A, Lazarus HH, Litzow MR, Loberiza, FL Jr., Marks DJ, McCarthy PL, Miller C, Milone G, Russell JA, Sierra J, Wiernik PH, Weisdorf D. Hematopoietic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia: Comparative Analysis of Autologous and Unrelated Donor Bone Marrow Transplantation. *Bone Marrow Transplant* 41:635-642, 2008
114. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, **Bishop MR**, Gress RE, Hakim FT. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. *Biol Blood Marrow Transplant* 14:290-300, 2008
115. Marks DI, Perez WS, He W, Zhang M-J, **Bishop MR**, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated Donor Stem Cell Transplantation for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research Analysis. *Blood* 112:426-434, 2008
116. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, **Bishop MR**, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. *Blood* 112:2092-100, 2008

117. **Bishop MR**, Dean RM, Steinberg S, Odom J, Pavletic SZ, Sportes C, Hardy N, Pittaluga S, Gress RE, Fowler DH. Reduced-intensity allogeneic stem cell transplantation for diffuse large B-cell lymphoma: clinical evidence of a graft-versus-lymphoma effect. *Ann Oncol* 19:1935-1940, 2008
118. Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, **Bishop MR**. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. *J Clin Oncol* 26:5735-41, 2008
119. Adelberg DE, **Bishop MR**. Emergencies related to systemic treatment of cancer including chemotherapy and hematopoietic stem cell transplantation. *Emerg Med Clin North Am* 27:311-31, 2009 (invited review)
120. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, **Bishop MR**. Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in non-Hodgkin's lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 15:223-230, 2009
121. Sportes C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, **Bishop MR**, Gress RE. Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. *Biol Blood Marrow Transplant* 15:963-70, 2009
123. Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, **Bishop MR**, Rader C. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. *Blood* 114:4494-502, 2009
124. Giralt S, **Bishop MR**. Principles and overview of allogeneic hematopoietic stem cell transplantation. *Cancer Treat Res* 144:1-21, 2009 (invited review)
125. **Bishop MR**, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Krumlauf M, Sportes C, Gress RH, Fowler DH. Differentiation of chemotherapy sensitivity by disease state correlates with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. *Cancer* 116:852-62, 2010
126. van den Brink MRM, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, **Bishop MR**. Relapse after allogeneic hematopoietic cell therapy. *Biol Blood Marrow Transplant* 16(1 Suppl):S138-45, 2010. (invited review)
127. Pulanic D, Cowen EW, Baird K, **Bishop MR**, Pavletic ZS. Development of severe sclerotic chronic GVHD during treatment with dasatinib. *Bone Marrow Transplant* 45:1469-70, 2010 (letter)
128. **Bishop MR**, Alyea 3rd EP, Cairo MS, Falkenburg JHF, June CH, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DH, Wu R, Giralt S. Introduction to the Reports from the National Cancer Institute 1st International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 16:563-4, 2010 (Editorial)
129. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, **Bishop MR**, Blazar BR, Falkenburg JHF. NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-tumor/leukemia Reaction. *Biol Blood Marrow Transplant* 16:565-86, 2010

130. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Tycko B, Mackall C, Zitvogel L, **Bishop MR**, Giralt SA, June CH. NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse Following Allogeneic Stem Cell Transplantation Unrelated to Graft Versus Tumor Effects: State of the Science. *Biol Blood Marrow Transplant* 16:709-28, 2010
131. Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, **Bishop MR**. EPOCH-F: a novel salvage regimen for multiple myeloma prior to reduced-intensity allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2010 Jul 26. [Epub ahead of print]
132. Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepioraka D, Riddell S, Sadelin, M, Young, JW, Giralt S, **Bishop M**. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematological Malignancies. *Biol Blood Marrow Transplant* 16:1037-69, 2010
133. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, **Bishop MR**, Weisdorf D. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. *Biol Blood Marrow Transplant*. 16:871-90, 2010
134. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, **Bishop MR**, Wayne AS. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias and Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 16:1187-211, 2010
135. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, **Bishop MR**, Wayne AS. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms and Lymphoid Malignancies. *Biol Blood Marrow Transplant*. 16:1325-46, 2010
136. Porter DL, Alyea EP, Antin JH, Delima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, **Bishop MR**, van Besien K. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 16:1467-503, 2010
137. Salit RB, **Bishop MR**, Pavletic SZ. Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma? *Curr Hematol Malig Rep*. 5:229-238, 2010 (invited review).

138. Salit RB, Shea YR, Gea-Banacloche J, Fahle GA, Abu-Asab M, Sugui JA, Carpenter AE, Quezado MM, **Bishop MR**, Kwon-Chung KJ. Death by Edible Mushroom: First report of *Volvariella volvacea* as an etiologic agent of invasive disease in a patient following double umbilical cord blood transplantation. *J Clin Microbiol.* 48:4329-32, 2010
139. Kröger N, Miyamura K, **Bishop MR**. minimal residual disease following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 17(1 Suppl):S94-100, 2011 (invited review)
140. Salit R, **Bishop MR**. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: A concise review. *Clin Lymphoma Myeloma Leuk.* 11:247-52, 2011. (review)
141. **Bishop MR**, Alyea 3rd EP, Cairo MS, Falkenburg JHF, June CH, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. NCI 1st International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. *Biol Blood Marrow Transplant* 17:443-54, 2011
142. Salit RB, **Bishop MR**. The evolving world of tumor lysis syndrome. *Oncology (Williston Park).* 25:378,380, 2011 (review)
143. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, **Bishop MR**, Wilson W, Straus SE. Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28 Year Experience in the United States. *Blood* 117:5835-49, 2011
144. Mitchell SA, Jacobsohn D, Thormann Powers KE, Carpenter PA, Flowers MED, Cowen EW, Schubert M, Turner M, Lee SJ, Martin P, **Bishop MR**, Baird K, Bolaños-Meade J, Boyd K, Fall-Dickson JM, Gerber LH, Guadagnini JP, Imanguli M, Krumlauf MC, Lawley L, Li L, Reeve BB, Clayton JA, Vogelsang GB, Steven Z. Pavletic SZ. A Multi-Center Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Inter-rater Reliability, and Minimum Detectable Change. *Biol Blood Marrow Transplant* 17:1619-29, 2011
145. Luger SM, Ringden O, Zhang MJ, Perez WS, **Bishop MR**, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA. Similar Outcomes Using Myeloablative Versus Reduced Intensity Allogeneic Transplant Preparative Regimens For AML Or MDS. *Bone Marrow Transplant.* 47:203-11, 2012
146. Grkovic CL, Baird K, Steinberg SM, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Hakim FT, Martires KJ, Avila DN, Taylor TN, Rowley SD, Zhang D, Fowler DH, **Bishop MR**, Gress RE, Pavletic SZ. Clinical laboratory markers of inflammation in assessing chronic graft versus host disease activity and NIH global severity. *Leukemia* 2011 Oct 18. doi: 10.1038/leu.2011.254. [Epub ahead of print]
147. Baird K, Fry TJ, Steinberg SM, **Bishop MR**, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL. Reduced Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultra-High Risk Pediatric Sarcomas. *Biol Blood Marrow Transplant* 2011 Sep 5. [Epub ahead of print]
148. Hardy NM, Mossoba ME, Hakim FT, Babb RR, Chow CK, Steinberg SM, Gea-Banacloche J, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Sportès C, Gress RE, Fowler DH,

Bishop MR. Phase I Trial of Costimulated, Type-2 Polarized Allogeneic T Cell Therapy for Metastatic Breast Cancer. *Clin Cancer Res* 17:6878-87, 2011

149. Salit RB, Fowler DH, Wilson WH, Pavletic SZ, Dunleavy K, Hakim F, Dean RM, Steinberg SM, Hughes T, Odom J, Kelly Bryant K, **Bishop MR.** Dose adjusted EPOCH-fludarabine with and without rituximab for lymphoid malignancies prior to reduced-intensity allogeneic hematopoietic stem cell transplantation. *J Clin Oncol.* 2012 Feb 6. [Epub ahead of print]

150. Bacher U, Talano JA, **Bishop MR.** Monitoring and preventing relapse after allogeneic hematopoietic stem cell transplantation for myeloid malignancies. *Biol Blood Marrow Transplant* 18(1 Suppl):S62-73, 2012 (invited review)

151. **Bishop MR.** The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia [podcast]. *J Clin Oncol* doi:10.1200/JCO.2011.55.5555

152. Hardy NM, Fellowes V, Rose J, Pittaluga S, Stetler-Stevenson M, Hakim FT, Steinberg SM, Odom J, Blacklock B, Layton P, Avila D, Taylor T, Fowler DH, Khuu H, Levine BL, June CH, Gress RE, **Bishop MR.** Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Therapy for Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood Blood.* 2012 Jan 30. [Epub ahead of print]

153. -----(b)(4)-----

-----.

154. -----(b)(4)-----

155. -----(b)(4)-----

Manuscripts submitted or in preparation:

1. -----(b)(4)-----

2. -----(b)(4)-----

3. -----(b)(4)-----

- (b)(4)-----

4. -----(b)(4)-----

- 5. -----(b)(4)-----

- 6. -----(b)(4)-----

- 7. -----(b)(4)-----

Book Chapters:

1. **Bishop MR** and Henslee-Downey PJ. "Secondary Malignancy following Bone Marrow Transplantation", Clinical Bone Marrow Transplant: A Textbook, ed.: Atkinson, K. Cambridge University Press, pp. 422-431, 1994
2. **Bishop MR**, Warkentin PI, Jackson JD, Bayever E, Iversen PL, Whalen VI, Lastovica J, Haines K, Kessinger A. "Antisense Oligonucleotide OL(1)p53 for in vitro Purging of Autologous Bone Marrow in Acute Myelogenous Leukemia", Advances in Bone Marrow Purging and Processing Fourth International Symposium, eds.: Gee A, Gross S, Worthington-White D, Wiley-Liss, pp. 183-187, 1994.
3. **Bishop MR**. "Mobilization Prior to Apheresis Procedure", Practical Considerations of Apheresis in Peripheral Blood Stem Cell Transplantation, eds.: Kessinger A and McMannis JD. COBE Laboratories, Inc., pp. 5-10, 1994.
4. Rana TM and **Bishop MR**. "Acute Lymphocytic Leukemia", Current Therapy in Cancer, ed: Foley JF, Vose JM, Armitage JO. W.B. Saunders, pp.315-321, 1994.
5. **Bishop MR**. "Gene Therapy", Current Therapy in Cancer, eds.: Foley JF, Vose JM, Armitage JO. W.B. Saunders, pp. 392-394, 1994.
6. Armitage JO, **Bishop MR**. "Bone Marrow Transplantation." Clinical Oncology, ed.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone, pp. 295-305, 1995.
7. **Bishop MR** and Coccia PF. "Tumor Lysis Syndrome." Clinical Oncology, ed.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone, pp. 557-561, 1995.
8. Bierman PJ, **Bishop MR**, and Armitage JO. "High-dose Chemotherapy with Cellular Support for Hematological Malignancies, Cell Therapy, eds.: Morstyn G, Sheridan W. Cambridge University Press, pp. 337-351, 1995.

9. Iversen PL, Copple BL, Tewary HK, Bayever E, and **Bishop MR**. "Continuous Infusion of Antisense Phosphorothioate Therapeutics", Methods in Molecular Medicine: Antisense Therapeutics, ed.: Agrawal S. Humana Press Inc., 11:201-212, 1996.
10. Sharp JG, Bishop M, Chan WC, Greiner T, Joshi SS, Kessinger A, Reed E, Sanger W, Tarantolo S, Traystman M, and Vose J. "Detection of Minimal Residual Disease in Hematopoietic Tissues", Bone Marrow Transplantation: Foundations for the 21st Century, eds.: Sackstein R, Janssen WE, Elfenbein GJ. New York Academy of Science, New York, NY, 770:242-261, 1995.
11. Armitage JO and **Bishop MR**. "Bone Marrow Transplantation", Yearbook of Cell and Tissue Transplantation, eds.: Lanza RP, Chick WL. Netherlands: Kluwer Academic Publishers, 3-12, 1996/97.
12. **Bishop, MR**. "Bone Marrow Transplantation from Unrelated Donors", American Society of Clinical Oncology Education Book, ed. Perry M. American Society of Clinical Oncology, Alexandria, VA, 1998.
13. Malone JM III, and **Bishop MR**. "Acute Lymphocytic Leukemia", Current Therapy in Cancer (second edition), eds.: Foley JF, Vose JM, Armitage JO. W.B. Saunders, 1999.
14. **Bishop MR**. "Stem Cell Transplantation for Chronic Myelogenous Leukemia: Indications and Timing" In: Current Controversies in Bone Marrow Transplantation. ed.: Bolwell BJ. Humana Press. pp. 83-94, 1999.
15. Sanger WG and **Bishop MR**. "Cytogenetics", Malignant Lymphoma, eds.: Hancock, Selby, MacLennan and Armitage, Chapman & Hall Ltd, 2000.
16. **Bishop MR** and Coccia PF. "Tumor Lysis Syndrome" Clinical Oncology (second edition), eds.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone, 2000.
17. **Bishop MR**. "Non-Myeloablative Allogeneic hematopoietic Stem Cell Transplantation as Adoptive Cellular Therapy"; Updates: Principles and Practice of Biologic Therapy of Cancer (Third edition), ed.: Rosenberg SA. Lippincollt, Williams, & Wilkins, 2001
18. **Bishop MR** and Henslee-Downey PJ. "Secondary Solid Tumors following Hematopoietic Stem Cell Transplantation", Clinical Bone Marrow Transplant: A Textbook (Third Edition), ed.: Atkinson, K. Cambridge University Press, 2003.
19. **Bishop MR** and Fowler DH. "Adoptive Immunotherapy for Malignant Disease", American Society of Clinical Oncology Education Book, ed. Perry M. American Society of Clinical Oncology, Alexandria, VA; pp. 22-8, 2003.
20. **Bishop MR**. "Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Solid Tumors", American Society of Clinical Oncology Education Book, ed. Perry M. American Society of Clinical Oncology, Alexandria, VA; pp. 256-65, 2003.
21. **Bishop MR**, Cairo M and Coccia PF. "Tumor Lysis Syndrome", Clinical Oncology (Third edition), eds.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone) pp. 987-992, 2004.
22. Hardy NM and **Bishop MR**. "Harnessing the Potential of Graft-versus-Tumor", Immunotherapy of Cancer, ed.: Disis ML, Humana Press Totowa, NJ; pp. 235 – 261, 2006
23. **Bishop MR**. "Principles of Hematopoietic Stem Cell Transplantation to Treat Hematologic Malignancies", Clinical Neoplastic Hematology, eds.: Bolwell B, Kalaycio M, Sekeres M. McGraw-Hill Professional; pp. 975-984, 2007
24. -----(b)(4)-----

- 25. Boyiadzis MM and **Bishop MR**. "Complications and Follow-up after Hematopoietic Stem Cell Transplantation", Hematology-Oncology Therapy, ed.: Boyiadzis MM, Lebowitz PF, Frame JN, Fojo T. McGraw-Hill Professional; pp. 674-693, 2007
- 26. Barrett AJ, Chao NJ, and **Bishop MR**. "Allogeneic Stem Cell Transplantation: Are We Curing More Patients?" American Society of Clinical Oncology Education Book, ed. Perry M. American Society of Clinical Oncology, Alexandria, VA; pp.387-96, 2006
- 27. Hardy NM and **Bishop MR**. "The Place of Stem Cell Transplantation in the Treatment of Breast Cancer", The Clinical Practice of Stem Cell Transplantation (Second edition), eds.: Treleaven J, Barrett AJ. Elsevier; pp. 123-136, 2009
- 28. Pavletic SZ and **Bishop MR**. "Hematopoietic Stem Cell Transplantation", Clinical Oncology (Fourth edition), eds.: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Churchill Livingstone, Philadelphia; pp. 501-512, 2008
- 29. Giralt S and **Bishop MR**. "Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation", Hematopoietic Stem Cell Transplantation, ed. **Bishop MR**. Springer, New York; pp. 1-22, 2009
- 30. -----(b)(4)-----

- 31. -----(b)(4)-----

Books:

- 1. Introduction and scientific editor for "Living with Lymphoma" by Adler EM, The John Hopkins University Press, Baltimore, 2005
- 2. Hematopoietic Stem Cell Transplantation. Series: Cancer Treatment and Research, **Bishop MR** (Editor). Springer, New York, 2009

NIH Protocols (1999 – 2011):

CC 96-C-0104: A Pilot Study of Paclitaxel/Cyclophosphamide and High-Dose Melphalan/Etoposide with Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer.

Role: Associate Investigator (patient care)

Study open date: 06/20/97; Study accrual to date = 110

CC 99-C-0143 (NCI Protocol # 3491): Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-myeloablative, HLA-matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Role: Study Chairperson

Study open date: 07/12/99; Study closure date: 03/05/03; Study accrual = 110

CC 00-C-0119: Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer.

Role: Principal Investigator.

Study open date: 04/18/00; Study closure date: 09/20/04; Study accrual = 52

CC 00-C-0078: Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer.

Role: Associate investigator.

CC 00- C-0121: A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors.

Role: Associate investigator.

CC 00-C-0201 (NCI Protocol #1029): Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient with Multiple Myeloma in the Setting of Non-myeloablative, HLA-matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Role: Principal Investigator.

Study open date: 06/08/00; Study accrual to date = 21

CC 00-C-0206 (CTEP Protocol NCI # 213): Phase I Study of Yttrium 90-labeled Monoclonal Antibody B3 with Autologous Stem Cell Support for Metastatic Breast Cancer

Role: Principal Investigator

Study open date: 04/21/00; Study closure date: 09/08/03; Study accrual number = 2

CC 01-C-0125: Pilot Study of Non-myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies.

Role: Clinical Chairperson

Study open date: 03/09/01; Study accrual to date = 22

CC 01-C-0144: Surveillance of Invasive Fungal Infections in Bone Marrow /Stem Cell and Solid Organ Transplantation Recipients and Other Immunocompromised Patients: A Prospective Study.

Role: Associate Investigator (protocol development, patient recruitment and care)

Study open date: 03/25/01; Study accrual to date = 64

CC 02-C-0259: Pilot Study of Allogeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas.

Role: Associate Investigator (protocol development)

Study open date: 07/01/02; Study accrual to date = 42

CC 03-C0-0077: A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation for Refractory or Relapsed Hematologic Malignancies, with Cyclosporine & Methotrexate for Graft-Versus-Host Disease Prophylaxis.

Role: Principal Investigator

Study open date: 12/30/02; Study closure date: 11/15/04; Study accrual = 62

CC 03-C-0040: A Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients with Previously Untreated Metastatic Breast Cancer; Vaccine-Induced Bias of T-Cell Repertoire Reconstitution after T-Cell Re-Infusion.

Role: Associate Investigator (protocol development; patient care)

Study open date: 08/26/02; Study accrual to date = 22

CC 03-C-0152: A Phase 1 Study of Subcutaneous "CYT 99 007" (Interleukin 7) in Patients with Refractory Non-Hematologic Malignancy.

Role: Associate Investigator (protocol development; patient care)

Study open date: 03/27/03; Study accrual to date = 21

CC 03-C-0205: A Phase I-II Safety, Tolerability and Pharmacokinetic Study of Ravuconazole for Prophylaxis of Invasive Fungal Infections in Patients Undergoing a Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant.

Role: Associate Investigator (protocol development, patient accrual, patient care)

Study open date: 05/23/03; Study termination date: 09/07/04; Study accrual = 27

CC 03-I-0025: Treatment of Chronic Graft Versus Host Disease with Extracorporeal Photopheresis.

Role: Associate Investigator (protocol development, patient accrual; patient care)

Study open date: 11/14/02; Study accrual to date = 13

03-CC-0028: Exploring the Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates.

Role: Associate Investigator (protocol development, patient accrual)

Study open date: 10/17/02; Study termination date: 08/29/05; Study accrual = 53

CC 04-C-0116: T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation from Haploidentical Related Donors for Hematologic Malignancies (HAPLO Part A).

Role: Principal Investigator.

Study open date: Study accrual to date = 2

CC 04-C-0055: Randomized Study of Sirolimus (Rapamycin) Generated Donor Th2 Cells and In Vivo Sirolimus for GVHD Prevention after Allogeneic HSCT for Hematologic Malignancy.

Role: Protocol Chairperson

Study open date: 12/01/03; Study accrual to date = 68

CC 04-C-0095: A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Systemic Lupus Erythematosus.

Role: Associate Investigator (protocol development; patient care)

Study open date: 12/15/03; Study accrual to date = 8

CC 04-C-0102: Hematologic Malignancy Biology Study.

Role: Associate Investigator (protocol development)

Study open date: 01/20/04; Study accrual to date = 21

CC 04-C-0131: Allogeneic Breast Protocol 2: Phase I Trial of T cell Exchange with Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for Metastatic Breast Cancer.

Role: Principal Investigator.

Study open date: 01/20/04; Study accrual = 11; Study closed to accrual 7/31/09

CC 04-C-0281: Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients with Chronic Graft-Versus-Host Disease.

Role: Associate Investigator (protocol development, patient accrual, patient care)

Study open date: 08/16/04; Study accrual to date = 41

CC 04-C-0288: Treatment of Patients with Metastatic Melanoma using a Transplant of Autologous Lymphocytes Reactive with Tumor Following a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body Irradiation, and Reconstitution with CD34+ Cells.

Role: Associate Investigator (protocol development, patient care)

Study open date: 08/16/04; Study accrual to date = 34

CC 05-C-9980: Adoptive Immunotherapy With Costimulated Tumor-Derived T Cells After Allogeneic Hematopoietic Stem Cell Transplantation.

Role: Principal Investigator

Study termination date: 09/30/05; Single patient trial approved by FDA

CC 04-C-0288D: Treatment of Patients with Metastatic Melanoma Using a Transplant of Autologous Lymphocytes Reactive with Tumor Following a Myeloablative Lymphocyte

Depleting Regimen of Chemotherapy, Total body Irradiation and Reconstitution with CD34+ Cells. (submitted to IRB)

Role: Associate Investigator (protocol development, patient care)

CC 06-C-0136: Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution with CD34+ Stem Cells in Metastatic Melanoma.

Role: Associate Investigator (protocol development, patient care)

CC 07-C-0064: Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes.

Role: Principal Investigator.

Study open date: 01/12/07; Study accrual to date = 10

CC 07-C-0195: Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders

Role: Principal Investigator

Study open date: 01/3/07; Study accrual to date = 68

CC 09-C-0210: Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders

Role: Principal Investigator

Study open date: 09/01/09; Study accrual to date = 3

CC 10-C-0054: Administration of anti-CD19-chimeric-antigen-receptor-transduced T cells from the original transplant donor to patients with recurrent or persistent B-cell malignancies after allogeneic stem cell transplantation

Role: Principal Investigator

FDA approval 10/27/09; IRB approval 1/11/10; Study accrual to date: 4

Revised February 2012